Prostate News Archive
07-Jul-2007
Genaerato discontinues phase II study of Lomucin, squalamine (PharmaBiz)
Genaera Corporation announced that, in conjunction with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), both parties have agreed for reasons of futility to discontinue the phase II study of Lomucin for the treatment of cystic fibrosis (CF). Genaera also announced that the phase 2 study of squalamine in prostate cancer, which is an investigator-initiated study funded by the Department of ... Threshold faces SEC suit on prostate drug (UPI)
U.S. firm Threshold Pharmaceuticals is facing a shareholders' class action suit alleging the firm hid liver problems with its potential prostate drug. Verdict still out on prostate test (Chicago Sun-Times)
Dave Bigg was in such good health he hadn't seen a doctor in 20 years. But after Bigg finally underwent a routine physical, he learned he had a suspicious score on a PSA prostate cancer screening test. Genaera Discontinues LOMUCIN(TM) In Cystic Fibrosis And Squalamine In Prostate Cancer Studies (Medical News Today)
Genaera Corporation (Nasdaq: GENR) today announced that, in conjunction with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), both parties have agreed for reasons of futility to discontinue the Phase 2 study of LOMUCIN(TM) for the treatment of cystic fibrosis (CF). [click link for full article] Prostate cancer drug may be subsidised (News Interactive)
prostate cancer sufferers should find out within the next fortnight whether an expensive treatment will be subsidised by the Federal Government.
Back to Prostate News Archive
